

# Direct to Patient (=D2P) Survey Results

Philippe Van der Hofstadt BeCRO



## 000

### What is Direct-to-Patient (D2P)?

Shipping clinical suppopulation
 packaging facility dire

depot or ients home

Shippi home

inical site directly to patients

Home health care prove to patients home



clinical supplies





### D2P Working Group

- Professional Associations
- FlandersBio, Lifetech Brussels, BioWin
- Pharma Companies
- CROs
- Patient/Patient Association
- Cabinet of Minister Social Affairs & Public Health
- AFMPS-FAGG





### D2P WG Objectives

- To ensure D2P shipments are allowed in Belgium without breaching ICH, legislation, nor GXP, nor declaration of Helsinki
- To position Belgium as an innovator in Clinical Research
- To confirm Belgian's competitive edge in CR
- To take a EU lead in lobbying on D2P shipments and partner with foreign stakeholders






### Survey on D2P


- Patient: 10 => 5 <a href="https://www.surveymonkey.co.uk/r/6TV6MQX">https://www.surveymonkey.co.uk/r/6TV6MQX</a>
- Sponsor: 22 => 15 https://www.surveymonkey.co.uk/r/D2PSponsor
- CRO: 18 => 16 https://www.surveymonkey.co.uk/r/RYSM8WYCRO
- Investigator: 64 => 62 <a href="https://www.surveymonkey.co.uk/r/vQHSKX2Investigators">https://www.surveymonkey.co.uk/r/vQHSKX2Investigators</a>






### Experience with D2P












### Where did you apply D2P?











### What % patients did accept D2P?


#### **Investigator with experience**



#### **Investigator without experience**



#### **Sponsor**



CRO

60,00% 50,00% 40,00% 30,00% 20,00% 10,00% 0,00% 67-100% 0% 1-33% 34-66% Other -Please specify


some trials not analysed, some trials without choice, therefore 100%


Less than 33% 8 Between 33% and 66% 15 **AFMP** More than 66%




### Patient perspective on D2P (n=5)


Patient preferred way of receiving the drugs









If you could receive your medication at home or via your local pharmacy, would you be more likely to participate in a trial?





## Would D2P be beneficial to CT?











### Would you do D2P again?










# How do you as investigator feel about the option of D2P? (n=35)







### Thank you

Questions or interest to contribute?

pvanderhofstadt@csmondemand.com



